Perspective Therapeutics, Inc. income statement CATX

Annual Quarterly

It recorded a net loss of $103.1 million. Diluted earnings per share were -$1.40. Across the 6 fiscal years shown, revenue shrank from $5.9 million in fiscal 2018 to $1.4 million in fiscal 2023, about 24.7% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Jun 30, 2022	FY 2021 Jun 30, 2021	FY 2020 Jun 30, 2020	FY 2019 Jun 30, 2019	FY 2018 Jun 30, 2018	FY 2017 Jun 30, 2017	FY 2016 Jun 30, 2016
Revenue	—	—	1 -86.7%	11 +7.4%	10 +3.9%	10 +32.3%	7 +23.5%	6	—	—
Cost of revenue	—	—	—	6 +25.3%	5 +8.3%	5 +6.8%	4 +4.6%	4 +4.0%	4 -15.5%	5 +4.5%
Gross profit	—	—	1	0 -100.0%	5 -0.1%	5 +68.2%	3 +65.4%	2 +119.8%	1 +549.6%	0 -22.8%
Research and development	84 +102.3%	42 +95.4%	21 +2407.2%	1 -40.4%	1 +26.7%	1 -23.6%	1 -15.6%	2 +80.9%	1 +82.8%	1 -14.1%
Selling, general and administrative	30 +13.6%	27 +26.3%	21 +151.6%	8 +17.4%	7 -5.5%	8 +10.2%	7 +0.4%	7 +9.6%	6 +21.2%	5 +32.1%
Operating income	-114 -25.0%	-91 -122.0%	-41 -537.8%	-6 -86.3%	-3 +0.9%	-3 +33.8%	-5 +21.9%	-7 -6.7%	-6 -24.1%	-5 -17.2%
Other income (expense)	9 -12.6%	10 +1152.6%	1 +601.7%	0 +101.7%	0 +96.7%	0 -72.7%	0 +279.3%	0 -80.0%	0 -60.9%	0 -43.4%
Equity in earnings of affiliates	-0 +75.0%	-0 +52.9%	-0	—	—	—	—	—	—	—
Pretax income	-104 -29.8%	-80 -100.5%	-40	—	—	—	—	—	—	—
Income tax	-1 +62.2%	-2 +20.9%	-3	0	0	0	0	0	0	0
Net income	-103 -30.1%	-79 -70.5%	-47 -539.5%	-7 -114.7%	-3 +1.7%	-3 +33.0%	-5 +23.2%	-7 -8.7%	-6 -30.8%	-5 -28.0%
Basic EPS	-1.40 -13.8%	-1.23 +29.3%	-1.74 -3380.0%	-0.05	—	—	—	—	—	—
Diluted EPS	-1.40 -13.8%	-1.23	—	—	—	—	—	—	—	—
Weighted average shares, basic	74 +14.6%	64 +140.7%	27 -81.2%	142	—	—	—	—	—	—
Weighted average shares, diluted	74 +14.6%	64	—	—	—	—	—	—	—	—
Other measures
Depreciation and amortization	3 +41.0%	2	—	—	—	—	—	—	0 -85.6%	0 -18.2%
EBITDA	-110 -24.5%	-89	—	—	—	—	—	—	-6 -35.3%	-5 -22.6%
Interest coverage	—	—	-487.39x	—	—	—	—	-6,729.00x	—	—
Margins
Gross margin	—	—	100.00%	0.00%	50.94%	52.93%	41.66%	31.10%	—	—
Operating margin	—	—	-2,855.02%	-59.46%	-34.28%	-35.91%	-71.83%	-113.61%	—	—
Pretax margin	—	—	-2,796.79%	—	—	—	—	—	—	—
Profit margin	—	—	-3,243.24%	-67.36%	-33.69%	-35.60%	-70.33%	-113.12%	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: CATX (NYSE)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Seattle, WA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 728387
Former names: IsoRay, Inc. (until Feb 16, 2023); Isoray, Inc. (until Feb 16, 2023); CENTURY PARK PICTURES CORP (until Aug 3, 2005)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.